HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.
J Virol Methods
; 243: 151-157, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-27894862
ABSTRACT
INTRODUCTION:
HIV genotyping is often unavailable in low and middle-income countries due to infrastructure requirements and cost. We compared genotype resistance testing in patients with virologic failure, by amplification of HIV pol gene, followed by "in-house" sequencing and commercial sequencing.METHODS:
Remnant plasma samples from adults and children failing second-line ART were amplified and sequenced using in-house and commercial di-deoxysequencing, and analyzed in Harare, Zimbabwe and at Stanford, U.S.A, respectively. HIV drug resistance mutations were determined using the Stanford HIV drug resistance database.RESULTS:
Twenty-six of 28 samples were amplified and 25 were successfully genotyped. Comparison of average percent nucleotide and amino acid identities between 23 pairs sequenced in both laboratories were 99.51 (±0.56) and 99.11 (±0.95), respectively. All pairs clustered together in phylogenetic analysis. Sequencing analysis identified 6/23 pairs with mutation discordances resulting in differences in phenotype, but these did not impact future regimens.CONCLUSIONS:
The results demonstrate our ability to produce good quality drug resistance data in-house. Despite discordant mutations in some sequence pairs, the phenotypic predictions were not clinically significant.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV
/
Análise de Sequência de DNA
/
Antirretrovirais
/
Técnicas de Genotipagem
Tipo de estudo:
Evaluation_studies
Limite:
Humans
País/Região como assunto:
Africa
/
America do norte
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article